Chemistry:GSK-971086

From HandWiki

GSK-971086 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK) for the potential treatment of sarcopenia.[1][2] As a SARM, GSK-971086 was designed to target androgen receptors in specific tissues, potentially offering therapeutic benefits for muscle wasting conditions while minimizing unwanted androgenic side effects. The compound underwent early-stage clinical trials to evaluate its safety, tolerability, and pharmacokinetic profile in human subjects.[3]

References

  1. ↑ "GSK 971086". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800027354. 
  2. ↑ "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs 29 (8): 881–891. August 2020. doi:10.1080/13543784.2020.1777275. PMID 32476495. 
  3. ↑ "Study to Test Safety, Tolerability and Blood Levels of GSK971086 after 1 Dose & 7 Days of Dosing in Healthy Adult Males". GSK Study Register. https://www.gsk-studyregister.com/en/trial-details/?id=SAR109935. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:GSK-971086&oldid=4032222"